|
1
|
Rouprêt M, Babjuk M, Burger M, Capoun O,
Cohen D, Compérat EM, Cowan NC, Dominguez-Escrig JL, Gontero P,
Hugh Mostafid A, et al: European association of urology guidelines
on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol.
79:62–79. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Green DA, Rink M, Xylinas E, Matin SF,
Stenzl A, Roupret M, Karakiewicz PI, Scherr DS and Shariat SF:
Urothelial carcinoma of the bladder and the upper tract: Disparate
twins. J Urol. 189:1214–1221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peyrottes A, Ouzaid I, Califano G, Hermieu
JF and Xylinas E: Neoadjuvant immunotherapy for muscle-invasive
bladder cancer. Medicina (Kaunas). 57:7692021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giudici N, Bonne F, Blarer J, Minoli M,
Krentel F and Seiler R: Characteristics of upper urinary tract
urothelial carcinoma in the context of bladder cancer: A narrative
review. Transl Androl Urol. 10:4036–4050. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Margulis V, Shariat SF, Matin SF, Kamat
AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD and Wood CG;
Upper Tract Urothelial Carcinoma Collaboration The Upper Tract
Urothelial Carcinoma Collaboration, : Outcomes of radical
nephroureterectomy: A series from the upper tract urothelial
carcinoma collaboration. Cancer. 115:1224–1233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Batata MA, Whitmore WF, Hilaris BS, Tokita
N and Grabstald H: Primary carcinoma of the ureter: A prognostic
study. Cancer. 35:1626–1632. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Collà Ruvolo C, Nocera L, Stolzenbach LF,
Wenzel M, Cucchiara V, Tian Z, Shariat SF, Saad F, Longo N,
Montorsi F, et al: Incidence and survival rates of contemporary
patients with invasive upper tract urothelial carcinoma. Eur Urol
Oncol. 4:792–801. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lughezzani G, Jeldres C, Isbarn H, Sun M,
Shariat SF, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, et
al: Nephroureterectomy and segmental ureterectomy in the treatment
of invasive upper tract urothelial carcinoma: A population-based
study of 2299 patients. Eur J Cancer. 45:3291–3297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kondo T and Tanabe K: Role of
lymphadenectomy in the management of urothelial carcinoma of the
bladder and the upper urinary tract. Int J Urol. 19:710–721. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chappidi MR, Kates M, Johnson MH, Hahn NM,
Bivalacqua TJ and Pierorazio PM: Lymph node yield and tumor
location in patients with upper tract urothelial carcinoma
undergoing nephroureterectomy affects survival: A U.S.
population-based analysis (2004–2012). Urol Oncol.
34:531.e15–531.e24. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lughezzani G, Jeldres C, Isbarn H, Shariat
SF, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, et
al: A critical appraisal of the value of lymph node dissection at
nephroureterectomy for upper tract urothelial carcinoma. Urology.
75:118–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roscigno M, Brausi M, Heidenreich A, Lotan
Y, Margulis V, Shariat SF, Van Poppel H and Zigeuner R:
Lymphadenectomy at the time of nephroureterectomy for upper tract
urothelial cancer. Eur Urol. 60:776–783. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deuker M, Rosiello G, Stolzenbach LF,
Martin T, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A,
Kluth LA, et al: Sex- and age-related differences in the
distribution of metastases in patients with upper urinary tract
urothelial carcinoma. J Natl Compr Canc Netw. 19:534–540. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto
M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, et
al: Role of lymph node dissection during radical nephroureterectomy
for upper urinary tract urothelial cancer: Multi-institutional
large retrospective study JCOG1110A. World J Urol. 35:1737–1744.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rouprêt M, Seisen T, Birtle AJ, Capoun O,
Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F,
Mariappan P, Hugh Mostafid A, et al: European association of
urology guidelines on upper urinary tract urothelial carcinoma:
2023 update. Eur Urol. 84:49–64. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Coleman JA, Clark PE, Bixler BR, Buckley
DI, Chang SS, Chou R, Hoffman-Censits J, Kulkarni GS, Matin SF,
Pierorazio PM, et al: Diagnosis and management of non-metastatic
upper tract urothelial carcinoma: AUA/SUO guideline. J Urol.
209:1071–1081. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akaza H, Koiso K and Niijima T: Clinical
evaluation of urothelial tumors of the renal pelvis and ureter
based on a new classification system. Cancer. 59:1369–1375. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matin SF, Sfakianos JP, Espiritu PN,
Coleman JA and Spiess PE: Patterns of lymphatic metastases in upper
tract urothelial carcinoma and proposed dissection templates. J
Urol. 194:1567–1574. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kondo T, Hara I, Takagi T, Kodama Y,
Hashimoto Y, Kobayashi H, Iizuka J, Omae K, Yoshida K and Tanabe K:
Template-based lymphadenectomy in urothelial carcinoma of the renal
pelvis: A prospective study. Int J Urol. 21:453–459. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mason RJ, Kassouf W, Bell DG, Lacombe L,
Kapoor A, Jacobsen N, Fairey A, Izawa J, Black P, Tanguay S, et al:
The contemporary role of lymph node dissection during
nephroureterectomy in the management of upper urinary tract
urothelial carcinoma: the Canadian experience. Urology. 79:840–845.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhai TS, Jin L, Zhou Z, Liu X, Liu H, Chen
W, Lu JY, Yao XD, Feng LM and Ye L: Effect of lymph node dissection
on stage-specific survival in patients with upper urinary tract
urothelial carcinoma treated with nephroureterectomy. BMC cancer.
19:12072019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Birtle A, Johnson M, Chester J, Jones R,
Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto
JWF, et al: Adjuvant chemotherapy in upper tract urothelial
carcinoma (the POUT trial): A phase 3, open-label, randomised
controlled trial. Lancet. 395:1268–1277. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu H, Ai JZ, Tan P, Lin TH, Jin X, Gong
LN, Lei HR, Yang L and Wei Q: Pretreatment elevated fibrinogen
level predicts worse oncologic outcomes in upper tract urothelial
carcinoma. Asian J Androl. 22:177–183. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tan P, Shi M, Chen J, Xu H, Xie N, Xu H,
Jiang Y, Ai JZ, Liu LR, Yang L and Wei Q: The preoperative serum
cystatin-C as an independent prognostic factor for survival in
upper tract urothelial carcinoma. Asian J Androl. 21:163–169. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saito K, Kawakami S, Ohtsuka Y, Fujii Y,
Masuda H, Kumagai J, Kobayashi T, Kageyama Y and Kihara K: The
impact of preoperative serum C-reactive protein on the prognosis of
patients with upper urinary tract urothelial carcinoma treated
surgically. BJU Int. 100:269–273. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu H, Tan P, Ai J, Huang Y, Lin T, Yang L
and Wei Q: Prognostic impact of preoperative albumin-globulin ratio
on oncologic outcomes in upper tract urothelial carcinoma treated
with radical nephroureterectomy. Clin Genitourin Cancer.
16:e1059–e1068. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rink M, Sharifi N, Fritsche HM, Aziz A,
Miller F, Kluth LA, Ngamsri T, Dahlem R, Chun FK, Shariat SF, et
al: Impact of preoperative anemia on oncologic outcomes of upper
tract urothelial carcinoma treated with radical nephroureterectomy.
J Urol. 191:316–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vartolomei MD, Mathieu R, Margulis V,
Karam JA, Rouprêt M, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI,
Fajkovic H, et al: Promising role of preoperative
neutrophil-to-lymphocyte ratio in patients treated with radical
nephroureterectomy. World J Urol. 35:121–130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kondo T, Hashimoto Y, Kobayashi H, Iizuka
J, Nakazawa H, Ito F and Tanabe K: Template-based lymphadenectomy
in urothelial carcinoma of the upper urinary tract: Impact on
patient survival. Int J Urol. 17:848–854. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kondo T, Nakazawa H, Ito F, Hashimoto Y,
Toma H and Tanabe K: Impact of the extent of regional
lymphadenectomy on the survival of patients with urothelial
carcinoma of the upper urinary tract. J Urol. 178:1212–1217. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kondo T, Hara I, Takagi T, Kodama Y,
Hashimoto Y, Kobayashi H, Iizuka J, Omae K, Ikezawa E, Yoshida K
and Tanabe K: Possible role of template-based lymphadenectomy in
reducing the risk of regional node recurrence after
nephroureterectomy in patients with renal pelvic cancer. Jpn J Clin
Oncol. 44:1233–1238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Burger M, Shariat SF, Fritsche HM,
Martinez-Salamanca JI, Matsumoto K, Chromecki TF, Ficarra V,
Kassouf W, Seitz C, Pycha A, et al: No overt influence of
lymphadenectomy on cancer-specific survival in organ-confined
versus locally advanced upper urinary tract urothelial carcinoma
undergoing radical nephroureterectomy: A retrospective
international, multi-institutional study. World J Urol. 29:465–472.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Duquesne I, Ouzaid I, Loriot Y, Moschini M
and Xylinas E: Lymphadenectomy for upper tract urothelial
carcinoma: A systematic review. J Clin Med. 8:11902019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stein JP, Cai J, Groshen S and Skinner DG:
Risk factors for patients with pelvic lymph node metastases
following radical cystectomy with en bloc pelvic lymphadenectomy:
Concept of lymph node density. J Urol. 170:35–41. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bolenz C, Shariat SF, Fernández MI,
Margulis V, Lotan Y, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R,
Weizer A, et al: Risk stratification of patients with nodal
involvement in upper tract urothelial carcinoma: Value of
lymph-node density. BJU Int. 103:302–306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM,
Dickinson SI, Lin HY and Spiess PE: Prospective clinical trial of
the feasibility and safety of modified retroperitoneal lymph node
dissection at time of nephroureterectomy for upper tract urothelial
carcinoma. BJU Int. 110:E475–E480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Abe T, Takada N, Matsumoto R, Osawa T,
Sazawa A, Maruyama S, Tsuchiya K, Harabayashi T, Minami K, Nagamori
S, et al: Outcome of regional lymphadenectomy in accordance with
primary tumor location on laparoscopic nephroureterectomy for
urothelial carcinoma of the upper urinary tract: A prospective
study. J Endourol. 29:304–309. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu H, Liang Y, Guan B, Shi Y, Gong Y, Li
J, Kong W, Liu J, Fang D, Liu L, et al: Aristolochic acid
mutational signature defines the low-risk subtype in upper tract
urothelial carcinoma. Theranostics. 10:4323–4333. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Novara G, De Marco V, Gottardo F, Dalpiaz
O, Bouygues V, Galfano A, Martignoni G, Patard JJ, Artibani W and
Ficarra V: Independent predictors of cancer-specific survival in
transitional cell carcinoma of the upper urinary tract:
multi-institutional dataset from 3 European centers. Cancer.
110:1715–1722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Secin FP, Koppie TM, Salamanca JI, Bokhari
S, Raj GV, Olgac S, Martignoni G, Patard JJ, Artibani W and Ficarra
V: Evaluation of regional lymph node dissection in patients with
upper urinary tract urothelial cancer. Int J Urol. 14:26–32. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Roscigno M, Cozzarini C, Bertini R,
Scattoni V, Freschi M, Da Pozzo LF, Briganti A, Gallina A,
Capitanio U, Colombo R, et al: Prognostic value of lymph node
dissection in patients with muscle-invasive transitional cell
carcinoma of the upper urinary tract. Eur Urol. 53:794–802. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cho KS, Choi HM, Koo K, Park SJ, Rha KH,
Choi YD, Chung BH, Cho NH, Yang SC and Hong SJ: Clinical
significance of lymph node dissection in patients with
muscle-invasive upper urinary tract transitional cell carcinoma
treated with nephroureterectomy. J Korean Med Sci. 24:674–678.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ouzzane A, Colin P, Ghoneim TP, Zerbib M,
De La Taille A, Audenet F, Saint F, Hoarau N, Adam E, Azemar MD, et
al: The impact of lymph node status and features on oncological
outcomes in urothelial carcinoma of the upper urinary tract (UTUC)
treated by nephroureterectomy. World J Urol. 31:189–197. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Abe T, Shinohara N, Muranaka M, Sazawa A,
Maruyama S, Osawa T, Harabayashi T, Kubota K, Matsuno Y, Shibata T,
et al: Role of lymph node dissection in the treatment of urothelial
carcinoma of the upper urinary tract: multi-institutional relapse
analysis and immunohistochemical re-evaluation of negative lymph
nodes. Eur J Surg Oncol. 36:1085–1091. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Roscigno M, Shariat SF, Margulis V,
Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A,
Bensalah K, et al: Impact of lymph node dissection on cancer
specific survival in patients with upper tract urothelial carcinoma
treated with radical nephroureterectomy. J Urol. 181:2482–2489.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Galsky MD, Witjes JA, Gschwend JE,
Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret
T, Shariat SF, et al: Adjuvant nivolumab in high-risk
muscle-invasive urothelial carcinoma: Expanded efficacy from
checkmate 274. J Clin Oncol. 43:15–21. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Abufaraj M, Li R, Meeks J and Shariat SF:
Cytoreductive surgery in patients with urothelial bladder cancer.
Eur Urol Focus. 9:278–279. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shigeta K, Matsumoto K, Ogihara K,
Murakami T, Anno T, Umeda K, Izawa M, Baba Y, Sanjo T, Shojo K, et
al: Does neoadjuvant chemotherapy have therapeutic benefit for
node-positive upper tract urothelial carcinoma? Results of a
multi-center cohort study. Urol Oncol. 40:105.e19–105.e26. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jung H, Giusti G, Fajkovic H, Herrmann T,
Jones R, Straub M, Baard J, Osther PJS and Brehmer M: Consultation
on UTUC, Stockholm 2018: Aspects of treatment. World J Urol.
37:2279–2287. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Galsky MD, Chen GJ, Oh WK, Bellmunt J,
Roth BJ, Petrioli R, Dogliotti L, Dreicer R and Sonpavde G:
Comparative effectiveness of cisplatin-based and carboplatin-based
chemotherapy for treatment of advanced urothelial carcinoma. Ann
Oncol. 23:406–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bajorin DF, Witjes JA, Gschwend JE,
Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat
SF, Park SH, et al: Adjuvant nivolumab versus placebo in
muscle-invasive urothelial carcinoma. N Engl J Med. 384:2102–2114.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li Z, Li X, Liu Y, Fang J, Zhang X and
Xiao K: Can American Joint Committee on Cancer prognostic groups be
individualized in patients undergoing surgery for Stage IV invasive
upper tract Urothelial Carcinoma? J Cancer. 12:2023–2029. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Abdel-Rahman O: Revisiting the prognostic
heterogeneity of AJCC Stage IV carcinomas of the upper urinary
tract. Clin Genitourin Cancer. 16:e859–e865. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Flaig TW, Spiess PE, Chair V, Abern M,
Agarwal N and Buyyounouski MK: NCCN Guidelines Version 3.2023
Bladder Cancer. National Comprehensive Cancer Network. Available
from:. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417
|
|
55
|
Dominguez-Escrig JL, Peyronnet B, Seisen
T, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM,
Gontero P, et al: Potential benefit of lymph node dissection during
radical nephroureterectomy for upper tract urothelial carcinoma: A
systematic review by the European association of urology guidelines
panel on non-muscle-invasive bladder cancer. Eur Urol Focus.
5:224–241. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Brausi MA, Gavioli M, De Luca G, Verrini
G, Peracchia G, Simonini G and Viola M: Retroperitoneal lymph node
dissection (RPLD) in conjunction with nephroureterectomy in the
treatment of infiltrative transitional cell carcinoma (TCC) of the
upper urinary tract: Impact on survival. Eur Urol. 52:1414–1418.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Matsumoto R, Abe T, Takada N, Minami K,
Harabayashi T, Nagamori S, Hatanaka KC, Yamashiro K, Kikuchi H,
Osawa T, et al: Oncologic outcomes of laparoscopic radical
nephroureterectomy in conjunction with template-based lymph node
dissection: An extended follow-up study. Urol Oncol.
38:933.e13–933.e18. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Furuse H, Matsushita Y, Yajima T, Kato T,
Suzuki T, Matsumoto R, Motoyama D, Sugiyama T, Otsuka A and Ozono
S: Systematic regional lymph node dissection for upper tract
urothelial carcinoma improves patient survival. Jpn J Clin Oncol.
47:239–246. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ikeda M, Matsumoto K, Sakaguchi K, Ishii
D, Tabata KI, Kurosawa K, Urakami S, Okaneya T and Iwamura M:
Effect of lymphadenectomy during radical nephroureterectomy in
locally advanced upper tract urothelial carcinoma. Clin Genitourin
Cancer. 15:556–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yoo S, You D, Jeong IG, Hong B, Hong JH,
Ahn H and Kim CS: Does lymph node dissection during
nephroureterectomy affect oncological outcomes in upper tract
urothelial carcinoma patients without suspicious lymph node
metastasis on preoperative imaging studies? World J Urol.
35:665–673. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Inokuchi J, Eto M, Hara T, Fujimoto H,
Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T and Ohyama C;
Cancer Registration Committee of the Japanese Urological
Association, : Impact of lymph node dissection on clinical outcomes
during nephroureterectomy in patients with clinically node-negative
upper urinary tract urothelial cancer: Subanalysis of a
multi-institutional nationwide case series of the Japanese
Urological Association. Jpn J Clin Oncol. 47:652–659. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Pearce SM, Pariser JJ, Patel SG, Steinberg
GD, Shalhav AL and Smith ND: The effect of surgical approach on
performance of lymphadenectomy and perioperative morbidity for
radical nephroureterectomy. Urol Oncol. 34:121.e15–21. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Winer AG, Vertosick EA, Ghanaat M, Corradi
RB, Carlsson S, Sjoberg DD, Sankin AI, Sfakianos JP, Cha EK,
Dalbagni G and Coleman JA: Prognostic value of lymph node yield
during nephroureterectomy for upper tract urothelial carcinoma.
Urol Oncol. 35:151.e9–151.e15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Dong F, Xu T, Wang X, Shen Y, Zhang X,
Chen S, Zhong S, Zhang M and Ding Q: Lymph node dissection could
bring survival benefits to patients diagnosed with clinically
node-negative upper urinary tract urothelial cancer: A
population-based, propensity score-matched study. Int J Clin Oncol.
24:296–305. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Brown GA, Busby JE, Wood CG, Pisters LL,
Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat
AM and Matin SF: Nephroureterectomy for treating upper urinary
tract transitional cell carcinoma: Time to change the treatment
paradigm? BJU Int. 98:1176–1180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li CC, Chang CH, Huang CP, Hong JH, Huang
CY, Chen IA, Lin JT, Lo CW, Yu CC, Tseng JS, et al: Comparing
oncological outcomes and surgical complications of hand-assisted,
laparoscopic and robotic nephroureterectomy for upper tract
urothelial carcinoma. Front Oncol. 11:7314602021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Clements MB, Krupski TL and Culp SH:
Robotic-assisted surgery for upper tract urothelial carcinoma: A
comparative survival analysis. Ann Surg Oncol. 25:2550–2562. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Peyronnet B, Seisen T, Dominguez-Escrig
JL, Bruins HM, Yuan CY, Lam T, Maclennan S, N'dow J, Babjuk M,
Comperat E, et al: Oncological outcomes of laparoscopic
nephroureterectomy versus open radical nephroureterectomy for upper
tract urothelial carcinoma: An European association of urology
guidelines systematic review. Eur Urol Focus. 5:205–223. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ishiyama Y, Kondo T, Kubota S, Shimada K,
Yoshida K, Takagi T, Iizuka J and Tanabe K: Therapeutic benefit of
lymphadenectomy for older patients with urothelial carcinoma of the
upper urinary tract: A propensity score matching study. Jpn J Clin
Oncol. 51:802–809. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Dindo D, Demartines N and Clavien PA:
Classification of surgical complications: A new proposal with
evaluation in a cohort of 6336 patients and results of a survey.
Ann Surg. 240:205–213. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Blom JH, van Poppel H, Maréchal JM,
Jacqmin D, Schröder FH, de Prijck L and Sylvester R; EORTC
Genitourinary Tract Cancer Group, : Radical nephrectomy with and
without lymph-node dissection: final results of European
Organization for Research and Treatment of Cancer (EORTC)
randomized phase 3 trial 30881. Eur Urol. 55:28–34. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kondo T, Takagi T and Tanabe K:
Therapeutic role of template-based lymphadenectomy in urothelial
carcinoma of the upper urinary tract. World J Clin Oncol.
6:237–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Janisch F, Shariat SF, Baltzer P, Fajkovic
H, Kimura S, Iwata T, Korn P, Yang L, Glybochko PV, Rink M and
Abufaraj M: Diagnostic performance of multidetector computed
tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): A
systematic review and meta-analysis. World J Urol. 38:1165–1175.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Millán-Rodríguez F, Palou J, de la
Torre-Holguera P, Vayreda-Martija JM, Villavicencio-Mavrich H and
Vicente Rodríguez J: Conventional CT signs in staging transitional
cell tumors of the upper urinary tract. Eur Urol. 35:318–322. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Pallauf M, D'Andrea D, König F, Laukhtina
E, Yanagisawa T, Rouprêt M, Daneshmand S, Djaladat H, Ghoreifi A,
Soria F, et al: Diagnostic accuracy of clinical lymph node staging
for upper tract urothelial cancer patients: A multicenter,
retrospective, observational study. J Urol. 209:515–524. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Rink M, Ehdaie B, Cha EK, Green DA,
Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic
H, et al: Stage-specific impact of tumor location on oncologic
outcomes in patients with upper and lower tract urothelial
carcinoma following radical surgery. Eur Urol. 62:677–684. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Al-Zubaidi M, Viswambaram P, McCombie S,
Liow E, Lenzo N, Ferguson T, Redfern AD, Gauci R and Hayne D:
89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial
Cancer Patients (ZiPUP): Protocol for a phase I trial of a novel
staging modality for urothelial carcinoma. BMJ Open.
12:e0604782022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Voskuilen CS, Schweitzer D, Jensen JB,
Nielsen AM, Joniau S, Muilwijk T, Necchi A, Azizi M, Spiess PE,
Briganti A, et al: Diagnostic Value of 18F-fluorodeoxyglucose
positron emission tomography with computed tomography for lymph
node staging in patients with upper tract urothelial carcinoma. Eur
Urol Oncol. 3:73–79. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zattoni F, Incerti E, Colicchia M,
Castellucci P, Panareo S, Picchio M, Fallanca F, Briganti A,
Moschini M, Gallina A, et al: Comparison between the diagnostic
accuracies of 18F-fluorodeoxyglucose positron emission
tomography/computed tomography and conventional imaging in
recurrent urothelial carcinomas: A retrospective, multicenter
study. Abdom Radiol (NY). 43:2391–2399. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Soubra A, Hayward D, Dahm P, Goldfarb R,
Froehlich J, Jha G and Konety BR: The diagnostic accuracy of
18F-fluorodeoxyglucose positron emission tomography and computed
tomography in staging bladder cancer: A single-institution study
and a systematic review with meta-analysis. World J Urol.
34:1229–1237. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Aydh A, Abufaraj M, Mori K, Quhal F,
Pradere B, Motlagh RS, Mostafaei H, Karakiewicz PI and Shariat SF:
Performance of fluoro-2-deoxy-D-glucose positron emission
tomography-computed tomography imaging for lymph node staging in
bladder and upper tract urothelial carcinoma: A systematic review.
Arab J Urol. 19:59–66. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Jensen TK, Holt P, Gerke O, Riehmann M,
Svolgaard B, Marcussen N and Bouchelouche K: Preoperative
lymph-node staging of invasive urothelial bladder cancer with
18F-fluorodeoxyglucose positron emission tomography/computed axial
tomography and magnetic resonance imaging: Correlation with
histopathology. Scand J Urol Nephrol. 45:122–128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Asai S, Fukumoto T, Tanji N, Miura N,
Miyagawa M, Nishimura K, Yanagihara Y, Shirato A, Miyauchi Y,
Kikugawa T and Yokoyama M: Fluorodeoxyglucose positron emission
tomography/computed tomography for diagnosis of upper urinary tract
urothelial carcinoma. Int J Clin Oncol. 20:1042–1047. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Tanaka H, Yoshida S, Komai Y, Sakai Y,
Urakami S, Yuasa T, Yamamoto S, Masuda H, Koizumi M, Kohno A, et
al: Clinical value of 18F-fluorodeoxyglucose positron emission
tomography/computed tomography in upper tract urothelial carcinoma:
Impact on detection of metastases and patient management. Urol Int.
96:65–72. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Takayanagi A, Takahashi A, Yorozuya W,
Okabe K, Kaji T and Takagi Y: The usefulness of positron emission
tomography/computed tomography in the diagnosis of metastasis in
patients with urothelial carcinoma. Nihon Hinyokika Gakkai Zasshi.
113:51–55. 2022.(In Japanese). PubMed/NCBI
|
|
86
|
Galili U: Cancer immunotherapy by
anti-gal-mediated in situ conversion of tumors into autologous
vaccines. The Natural Anti-gal Antibody as Foe Turned Friend in
Medicine, . 1st edition. Elsevier; Amsterdam: pp. 171–198. 2018
|
|
87
|
Nayak B, Dogra PN, Naswa N and Kumar R:
Diuretic 18F-FDG PET/CT imaging for detection and locoregional
staging of urinary bladder cancer: Prospective evaluation of a
novel technique. Eur J Nucl Med Mol Imaging. 40:386–393. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Jana S and Blaufox MD: Nuclear medicine
studies of the prostate, testes, and bladder. Semin Nucl Med.
36:51–72. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Sassa N, Kato K, Abe S, Iwano S, Ito S,
Ikeda M, Shimamoto K, Yamamoto S, Yamamoto T, Gotoh M and Naganawa
S: Evaluation of 11C-choline PET/CT for primary diagnosis and
staging of urothelial carcinoma of the upper urinary tract: A pilot
study. Eur J Nucl Med Mol Imaging. 41:2232–2241. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Polom W, Cytawa W, Polom A, Frankiewicz M,
Szurowska E, Lass P and Matuszewski M: Challenging visualization of
sentinel lymph nodes in upper urinary tract urothelial carcinoma. J
Clin Med. 10:54652021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Lebastchi AH, Gupta N, DiBianco JM, Piert
M, Davenport MS, Ahdoot MA, Gurram S, Bloom JB, Gomella PT,
Mehralivand S, et al: Comparison of cross-sectional imaging
techniques for the detection of prostate cancer lymph node
metastasis: A critical review. Transl Androl Urol. 9:1415–1427.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Fortuin AS, Smeenk RJ, Meijer HJ, Witjes
AJ and Barentsz JO: Lymphotropic nanoparticle-enhanced MRI in
prostate cancer: Value and therapeutic potential. Curr Urol Rep.
15:3892014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Birkhäuser FD, Studer UE, Froehlich JM,
Triantafyllou M, Bains LJ, Petralia G, Vermathen P, Fleischmann A
and Thoeny HC: Combined ultrasmall superparamagnetic particles of
iron oxide-enhanced and diffusion-weighted magnetic resonance
imaging facilitates detection of metastases in normal-sized pelvic
lymph nodes of patients with bladder and prostate cancer. Eur Urol.
64:953–960. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Caglic I and Barrett T: Diffusion-weighted
imaging (DWI) in lymph node staging for prostate cancer. Transl
Androl Urol. 7:814–823. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Woo S, Suh CH, Kim SY, Cho JY and Kim SH:
The diagnostic performance of MRI for detection of lymph node
metastasis in bladder and prostate cancer: An updated systematic
review and diagnostic meta-analysis. AJR Am J Roentgenol.
210:W95–W109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Shamis SAK, Edwards J and McMillan DC: The
relationship between carbonic anhydrase IX (CAIX) and patient
survival in breast cancer: Systematic review and meta-analysis.
Diagn Pathol. 18:462023. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Venkat S, Khan AI, Lewicki PJ, Borregales
L and Scherr DS: Novel nomograms to predict muscle invasion and
lymph node metastasis in upper tract urothelial carcinoma. Urol
Oncol. 40:108.e11–108.e17. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Li WM, Chan TC, Huang SK, Wu WJ, Ke HL,
Liang PI, Wei YC, Shiue YL and Li CF: Prognostic utility of FBLN2
expression in patients with urothelial carcinoma. Front Oncol.
10:5703402020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Ibrahim AM, Sabet S, El-Ghor AA, Kamel N,
Anis SE, Morris JS and Stein T: Fibulin-2 is required for basement
membrane integrity of mammary epithelium. Sci Rep. 8:141392018.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
de Vega S, Iwamoto T and Yamada Y:
Fibulins: Multiple roles in matrix structures and tissue functions.
Cell Mol Life Sci. 66:1890–1902. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Argraves WS, Greene LM, Cooley MA and
Gallagher WM: Fibulins: Physiological and disease perspectives.
EMBO Rep. 4:1127–1131. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Timpl R, Sasaki T, Kostka G and Chu ML:
Fibulins: A versatile family of extracellular matrix proteins. Nat
Rev Mol Cell Biol. 4:479–489. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Baird BN, Schliekelman MJ, Ahn YH, Chen Y,
Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, et al:
Fibulin-2 is a driver of malignant progression in lung
adenocarcinoma. PLoS One. 8:e670542013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Senapati S, Gnanapragassam VS, Moniaux N,
Momi N and Batra SK: Role of MUC4-NIDO domain in the MUC4-mediated
metastasis of pancreatic cancer cells. Oncogene. 31:3346–3356.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Mohammad T, Arif K, Alajmi MF, Hussain A,
Islam A, Rehman MT and Hassan I: Identification of high-affinity
inhibitors of pyruvate dehydrogenase kinase-3: Towards therapeutic
management of cancer. J Biomol Struct Dyn. 39:586–594. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhu J, Zheng G, Xu H, Jin X, Tang T and
Wang X: Expression and prognostic significance of pyruvate
dehydrogenase kinase 1 in bladder urothelial carcinoma. Virchows
Arch. 477:637–649. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Woolbright BL, Choudhary D, Mikhalyuk A,
Trammel C, Shanmugam S, Abbott E, Pilbeam CC and Taylor JA III: The
role of pyruvate dehydrogenase kinase-4 (PDK4) in bladder cancer
and chemoresistance. Mol Cancer Ther. 17:2004–2012. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Kuo YH, Chan TC, Lai HY, Chen TJ, Wu LC,
Hsing CH and Li CF: Overexpression of pyruvate dehydrogenase
kinase-3 predicts poor prognosis in urothelial carcinoma. Front
Oncol. 11:7491422021. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Posey KL, Coustry F and Hecht JT:
Cartilage oligomeric matrix protein: COMPopathies and beyond.
Matrix Biol. 71-72:161–173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Englund E, Bartoschek M, Reitsma B,
Jacobsson L, Escudero-Esparza A, Orimo A, Leandersson K, Hagerling
C, Aspberg A, Storm P, et al: Cartilage oligomeric matrix protein
contributes to the development and metastasis of breast cancer.
Oncogene. 35:5585–5596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Liu TT, Liu XS, Zhang M, Liu XN, Zhu FX,
Zhu FM, Ouyang SW, Li SB, Song CL, Sun HM, et al: Cartilage
oligomeric matrix protein is a prognostic factor and biomarker of
colon cancer and promotes cell proliferation by activating the Akt
pathway. J Cancer Res Clin Oncol. 144:1049–1063. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Norman GL, Gatselis NK, Shums Z, Liaskos
C, Bogdanos DP, Koukoulis GK and Dalekos GN: Cartilage oligomeric
matrix protein: A novel non-invasive marker for assessing cirrhosis
and risk of hepatocellular carcinoma. World J Hepatol. 7:1875–1883.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Kuo YH, Lai HY, Chan TC, Hsing CH, Huang
SK, Hsieh KL, Chen TJ, Li WS, Lu JC and Li CF: Upregulation of
cartilage oligomeric matrix protein predicts poor prognosis in
urothelial carcinoma. Onco Targets Ther. 15:727–740. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Li WM, Ke HL, Kuo YH, Lai HY, Chan TC,
Hsing CH, Hsieh KL, Li WS, Chen TJ, Wei YC, et al: High MT2A
expression predicts worse prognosis in patients with urothelial
carcinoma. Oncology. 100:485–497. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Nishikawa M, Miyake H, Kurahashi T and
Fujisawa M: Significance of multiple preoperative laboratory
abnormalities as prognostic indicators in patients with urothelial
carcinoma of the upper urinary tract following radical
nephroureterectomy. Int J Clin Oncol. 23:151–157. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Mori K, Janisch F, Mostafaei H, Kimura S,
Lysenko I, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M,
Margulis V, et al: Prognostic role of preoperative De Ritis ratio
in upper tract urothelial carcinoma treated with
nephroureterectomy. Urol Oncol. 38:601.e17–601.e24. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Wang K, Diao F, Ye Z, Zhang X, Zhai E, Ren
H, Li T, Wu H, He Y, Cai S and Chen J: Prognostic value of systemic
immune-inflammation index in patients with gastric cancer. Chin J
Cancer. 36:752017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zhang Y, Chen B, Wang L, Wang R and Yang
X: Systemic immune-inflammation index is a promising noninvasive
marker to predict survival of lung cancer: A meta-analysis.
Medicine (Baltimore). 98:e137882019. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang L, Wang C, Wang J, Huang X and Cheng
Y: A novel systemic immune-inflammation index predicts survival and
quality of life of patients after curative resection for esophageal
squamous cell carcinoma. J Cancer Res Clin Oncol. 143:2077–2086.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Jan HC, Wu KY, Tai TY, Weng HY, Yang WH,
Ou CH and Hu CY: The systemic immune-inflammation index (SII)
increases the prognostic significance of lymphovascular invasion in
upper tract urothelial carcinoma after radical nephroureterectomy.
Cancer Manag Res. 14:3139–3149. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Kobayashi S, Ito M, Takemura K, Suzuki H,
Yonese I and Koga F: Preoperative models incorporating the systemic
immune-inflammation index for predicting prognosis and muscle
invasion in patients with non-metastatic upper tract urothelial
carcinoma. Int J Clin Oncol. 27:574–584. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI
|
|
125
|
Therkildsen C, Eriksson P, Höglund M,
Jönsson M, Sjödahl G, Nilbert M and Liedberg F: Molecular subtype
classification of urothelial carcinoma in Lynch syndrome. Mol
Oncol. 12:1286–1295. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Pradere B, Lotan Y and Roupret M: Lynch
syndrome in upper tract urothelial carcinoma: Significance,
screening, and surveillance. Curr Opin Urol. 27:48–55. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Audenet F, Colin P, Yates DR, Ouzzane A,
Pignot G, Long JA, Soulie M, Phé V, Bensadoun H, Guy L, et al: A
proportion of hereditary upper urinary tract urothelial carcinomas
are misclassified as sporadic according to a multi-institutional
database analysis: Proposal of patient-specific risk identification
tool. BJU Int. 110:E583–E589. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Ju JY, Mills AM, Mahadevan MS, Fan J, Culp
SH, Thomas MH and Cathro HP: Universal lynch syndrome screening
should be performed in all upper tract urothelial carcinomas. Am J
Surg Pathol. 42:1549–1555. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Gayhart MG, Johnson N, Paul A, Quillin JM,
Hampton LJ, Idowu MO and Smith SC: Universal mismatch repair
protein screening in upper tract urothelial carcinoma. Am J Clin
Pathol. 154:792–801. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Rasmussen M, Madsen MG and Therkildsen C:
Immunohistochemical screening of upper tract urothelial carcinomas
for lynch syndrome diagnostics: A systematic review. Urology.
165:44–53. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Vuky J, Balar AV, Castellano D, O'Donnell
PH, Grivas P, Bellmunt J, Powles T, Bajorin D, Hahn NM, Savage MJ,
et al: Long-term outcomes in KEYNOTE-052: Phase II study
investigating first-line pembrolizumab in cisplatin-ineligible
patients with locally advanced or metastatic urothelial cancer. J
Clin Oncol. 38:2658–2666. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Balar AV, Galsky MD, Rosenberg JE, Powles
T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J,
Perez-Gracia JL, et al: Atezolizumab as first-line treatment in
cisplatin-ineligible patients with locally advanced and metastatic
urothelial carcinoma: A single-arm, multicentre, phase 2 trial.
Lancet. 389:67–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y,
Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK,
et al: Pembrolizumab as second-line therapy for advanced urothelial
carcinoma. N Engl J Med. 376:1015–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Loriot Y, Necchi A, Park SH, Garcia-Donas
J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B,
Varlamov S, et al: Erdafitinib in locally advanced or metastatic
urothelial carcinoma. N Engl J Med. 381:338–348. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Fujii Y, Sato Y, Suzuki H, Kakiuchi N,
Yoshizato T, Lenis AT, Maekawa S, Yokoyama A, Takeuchi Y, Inoue Y,
et al: Molecular classification and diagnostics of upper urinary
tract urothelial carcinoma. Cancer Cell. 39:793–809.e8. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Seisen T, Colin P, Hupertan V, Yates DR,
Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G,
et al: Postoperative nomogram to predict cancer-specific survival
after radical nephroureterectomy in patients with localised and/or
locally advanced upper tract urothelial carcinoma without
metastasis. BJU Int. 114:733–740. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Seisen T, Peyronnet B, Dominguez-Escrig
JL, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM,
Cowan NC, et al: Oncologic outcomes of kidney-sparing surgery
versus radical nephroureterectomy for upper tract urothelial
carcinoma: A systematic review by the EAU non-muscle invasive
bladder cancer guidelines panel. Eur Urol. 70:1052–1068. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Leow JJ, Chong YL, Chang SL, Valderrama
BP, Powles T and Bellmunt J: Neoadjuvant and adjuvant chemotherapy
for upper tract urothelial carcinoma: A 2020 systematic review and
meta-analysis, and future perspectives on systemic therapy. Eur
Urol. 79:635–654. 2021. View Article : Google Scholar : PubMed/NCBI
|
